fingolimod hydrochloride has been researched along with siponimod in 24 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (siponimod) | Trials (siponimod) | Recent Studies (post-2010) (siponimod) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 127 | 20 | 124 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (20.83) | 24.3611 |
| 2020's | 19 (79.17) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, RR; Dinallo, RM; Fryer, RM; Harrington, KE; Harrison, PC; Horan, JC; Modis, LK; Muthukumarana, A; Nodop Mazurek, S; Patnaude, L; Reinhart, GA | 1 |
| Dolgin, E | 1 |
| Beil, M; Danhof, M; Feldman, D; Fu, F; Jin, L; Luttringer, O; Ploeger, BA; Rigel, DF; Snelder, N; Stanski, DR; Webb, RL | 1 |
| Chaudhry, BZ; Cohen, JA; Conway, DS | 1 |
| Diallo, R; Hiepe, F; Kohler, S; Meisel, A; Pelz, A; Schaffert, H | 1 |
| Kondo, T | 1 |
| Abdelshafy, AAA; Chu, X; Elsaid, KMK; Elshawwaf, M; Ghobrial, RM; Kloc, M; Uosef, A; Vaughn, N | 1 |
| Ryan, KB; Sartawi, Z; Waeber, C | 1 |
| Ghobrial, RM; Kloc, M | 1 |
| Chun, J; Giovannoni, G; Hunter, SF | 1 |
| Cohen, JA; McGinley, MP | 1 |
| Adlard, N; Brennan, R; Cameron, C; Dahlke, F; Drudge, C; Haltner, A; Samjoo, IA; Spin, P; Worthington, E | 1 |
| Bonavita, S; Miele, G; Sparaco, M | 1 |
| Kolontareva, YM; Krasnov, VS | 1 |
| Berger, J; Campbell Cree, BA; DeLasHeras, V; Greenberg, BM; Hach, T; Hemmer, B; Kilaru, A; Kundu, U; Sullivan, R; Ward, BJ | 1 |
| Gu, ZC; Lv, Y; Ma, CL; Zhao, Z; Zhong, MK | 1 |
| Busra Azizoglu, Z; Canatan, H; Eken, A; Zehra Okus, F | 1 |
| Apóstolos-Pereira, SL; Callegaro, D; Castrillo, BB; Silva, GD | 1 |
| Asahi, M; Culp, C; Foos, WF; Patronas, M | 1 |
| Bigaud, M; Ekici, A; Enders, M; Kapitza, C; Kirchner, P; Kuerten, S; Weier, A; Wörl, J | 1 |
| Bigaud, M; Brinkmann, V; Dahlke, F; de Micco, M; Graham, G; Hach, T; Nicoletti, F; Petricoul, O; Piani-Meier, D; Shakeri-Nejad, K; Turrini, R | 1 |
| Achiron, A; Angelucci, F; Halusková, S; Hartung, HP; Mareš, J; Pavelek, Z; Štourač, P; Tichá, V; Vališ, M | 1 |
| Bermudez, M; Nguyen, TN; Wolber, G; Wunsch, F | 1 |
| Benedetti, MD; Capobussi, M; Castellini, G; Featherstone, R; Filippini, G; Frau, S; Gonzalez-Lorenzo, M; Lucenteforte, E; Perduca, V; Tramacere, I; Virgili, G | 1 |
9 review(s) available for fingolimod hydrochloride and siponimod
| Article | Year |
|---|---|
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
Topics: Animals; Azetidines; Benzyl Compounds; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunologic Factors; Indans; Indoles; Multiple Sclerosis; Naphthalenes; Oxadiazoles; Propanolamines; Receptors, Lysosphingolipid; Thiazoles; Treatment Outcome | 2017 |
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Topics: Animals; Azetidines; Benzyl Compounds; Fingolimod Hydrochloride; Humans; Indans; Multiple Sclerosis; Oxadiazoles; Prodrugs; Signal Transduction; Sphingosine-1-Phosphate Receptors | 2021 |
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
Topics: Animals; Azetidines; Benzyl Compounds; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immune System Diseases; Indans; Multiple Sclerosis; Nervous System Diseases; Oxadiazoles; Signal Transduction; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Thiazoles | 2021 |
[Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
Topics: Azetidines; Benzyl Compounds; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive | 2021 |
Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
Topics: Azetidines; Benzyl Compounds; Bradycardia; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Humans; Hypertension; Indans; Multiple Sclerosis; Oxadiazoles; Randomized Controlled Trials as Topic; Risk; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors | 2021 |
Is there a role for off-label high-efficacy disease-modifying drugs in progressive multiple sclerosis? A network meta-analysis.
Topics: Azetidines; Benzyl Compounds; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Network Meta-Analysis; Off-Label Use; Rituximab | 2022 |
Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
Topics: COVID-19; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; SARS-CoV-2; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors | 2023 |
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neurodegenerative Diseases; Recurrence; Risk Assessment | 2023 |
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Topics: Adolescent; Adult; Alemtuzumab; Azathioprine; Cladribine; Daclizumab; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Immunotherapy; Interferon beta-1a; Interferon beta-1b; Male; Multiple Sclerosis; Natalizumab; Network Meta-Analysis; Rituximab; Young Adult | 2023 |
15 other study(ies) available for fingolimod hydrochloride and siponimod
| Article | Year |
|---|---|
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
Topics: Animals; Azetidines; Benzyl Compounds; Bradycardia; Cells, Cultured; Drug Evaluation, Preclinical; Fingolimod Hydrochloride; Humans; Hypertension; Immunosuppressive Agents; Male; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Substrate Specificity | 2012 |
Therapies: Progressive steps.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, CD20; Azetidines; B-Lymphocytes; Benzamides; Benzyl Compounds; Blood-Brain Barrier; Clinical Trials as Topic; Disease Progression; Dogs; Drug Approval; Fingolimod Hydrochloride; Hope; Humans; Male; Mice; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Piperidines; Precision Medicine; Pyridines; Rituximab; Thiazoles; Ubiquinone; United States; United States Food and Drug Administration | 2016 |
Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach.
Topics: Animals; Azetidines; Benzyl Compounds; Cardiovascular System; Computational Biology; Fingolimod Hydrochloride; Heart Rate; Male; Models, Biological; Rats; Receptors, Lysosphingolipid | 2017 |
S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset.
Topics: Animals; Antibody Formation; Azetidines; Benzyl Compounds; Cytokines; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Male; Mice; Mice, Inbred C57BL; Myasthenia Gravis, Autoimmune, Experimental; Plasma Cells; Receptors, Lysosphingolipid; T-Lymphocytes | 2018 |
[New Arrival of Disease Modifying Drugs Initiates New Era in Multiple Sclerosis Treatment in Japan].
Topics: Antibodies, Monoclonal, Humanized; Azetidines; Benzyl Compounds; Clinical Trials as Topic; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferons; Japan; Multiple Sclerosis; Natalizumab | 2020 |
Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages.
Topics: Actin Cytoskeleton; Animals; Azetidines; Benzyl Compounds; Cell Membrane; Chemokine CCL2; Down-Regulation; Fingolimod Hydrochloride; Graft Rejection; Humans; Lysophospholipids; Macrophages; Membrane Proteins; Mice; Multiple Sclerosis; Organ Transplantation; Phosphoric Monoester Hydrolases; RAW 264.7 Cells; Receptors, Interleukin-8A; rhoA GTP-Binding Protein; Signal Transduction; Sphingosine; United States; United States Food and Drug Administration | 2020 |
Bone regenerative potential of the selective sphingosine 1-phosphate receptor modulator siponimod: In vitro characterisation using osteoblast and endothelial cells.
Topics: Azetidines; Benzyl Compounds; Bone Regeneration; Cell Physiological Phenomena; Cells, Cultured; Cyclic AMP; Fingolimod Hydrochloride; Human Umbilical Vein Endothelial Cells; Humans; Osteoblasts; Sphingosine 1 Phosphate Receptor Modulators | 2020 |
The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.
Topics: Azetidines; Benzyl Compounds; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Enzyme Inhibitors; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; rhoA GTP-Binding Protein; SARS-CoV-2 | 2020 |
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses.
Topics: Antibodies, Monoclonal, Humanized; Azetidines; Benzyl Compounds; Clinical Trials, Phase III as Topic; Disease Progression; Feasibility Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propensity Score | 2021 |
Severe lymphopenia switching from Fingolimod to Siponimod.
Topics: Azetidines; Benzyl Compounds; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting | 2021 |
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series.
Topics: Adolescent; Adult; Aged; Azetidines; Benzyl Compounds; Child; Clinical Trials as Topic; Comorbidity; COVID-19; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Product Surveillance, Postmarketing; Retrospective Studies; Severity of Illness Index; Young Adult | 2021 |
S1P analogues SEW2871, BAF312 and FTY720 affect human Th17 and Treg generation ex vivo.
Topics: Animals; Azetidines; Benzyl Compounds; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interleukin-23; Lysophospholipids; Mice; Neurodegenerative Diseases; Oxadiazoles; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes, Regulatory; Th17 Cells; Thiophenes | 2022 |
Siponimod-related bilateral cystoid macular oedema and intravenous fluorescein angiographic findings in a patient with stable proliferative diabetic retinopathy without history of diabetic macular oedema.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Fingolimod Hydrochloride; Fluoresceins; Humans; Macular Edema; Visual Acuity | 2022 |
Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis.
Topics: Animals; Benzyl Compounds; Central Nervous System; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Mice; Multiple Sclerosis | 2022 |
Structural determinants of sphingosine-1-phosphate receptor selectivity.
Topics: Fingolimod Hydrochloride; Ligands; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors; Structure-Activity Relationship | 2023 |